Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News on Pharma

Wegovy maker Novo Nordisk’s chair and six other board members step down

Surprise shake-up follows row with majority shareholder, which seeks ‘extensive reconfiguration’

The Guardian - UK

CSL and Optus pay millions to executives despite paying no company tax in Australia

Biotech company argues high pay is required to retain and attract ‘world-class’ talent

The Guardian - AU

Ozempic-maker Novo Nordisk To Shake Up Board

Denmark's Novo Nordisk said Tuesday it would replace more than half of its board, including the chair, as the Ozempic and Wegovy maker restructures in the face of rising competition for its anti-obesity treatments.

International Business Times

From analysis to the latest developments in health,
read the most diverse news in one place.

The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly.

Biotech stocks Disc Medicine and Revolution Medicines jumped Friday after the duo received some of the first CNPVs.

Investors Business Daily

Eli Lilly Sets Ambitious Sustainability Goals Despite Headwinds

Eli Lilly's prescription for growth and sustainability includes a strong drug pipeline, revenue growth and energy investments.

Investors Business Daily

Trump announces plan to lower cost of IVF drugs

The effort would pair two Trump priorities: lowering drug prices and making IVF treatment more affordable.

Axios

Omeros Catapults 154% On A Surprise $2.1 Billion Deal With Novo Nordisk

Omeros stock catapulted Wednesday after Novo Nordisk agreed to pay up to $2.1 billion to license its experimental treatment.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

PPE Medpro fails to meet deadline to repay Government almost £122m after ruling

Mrs Justice Cockerill previously ruled that PPE Medpro had breached a contract for millions of surgical gowns during the coronavirus pandemic.

Evening Standard

This Pharma Play, The IBD Stock Of The Day, Is Offering Another Entry Amid 100% Advance This Year

Alnylam stock has soared 100% in the 2025 stock market.

Investors Business Daily

Chronic Drug Shortages Frustrate EU Pharmacists, Patients

At a drug wholesaler warehouse in Belgium, shelves are emptier than they used to be.

International Business Times

Prescription drug coverage options are shrinking for Medicare shoppers

Fewer choices may be on the menu again as Medicare patients shop for prescription coverage this fall

The Independent UK

TikTok influencers fuelling parallel market for unlicensed weight-loss drug

Guardian finds a thriving trade on Telegram for retatrutide, which is still in clinical trials and illegal to sell

The Guardian - UK

AstraZeneca makes deal with Trump to lower drug prices and avoid tariffs

Company will sell some medicines at a discount to government’s Medicaid health plan in exchange for tariff relief

The Guardian - US

PPE Medpro partners willing to discuss ‘possible settlement’ of Covid gowns case

The Baroness Michelle Mone-linked company was ordered to pay back nearly £122 million due to a breach of contract

Evening Standard

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Rhythm Pharma Stock Gears Up For Its Next Move

This biotech stock has gained around 80% so far this year. It has formed a new base.

Investors Business Daily

Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out

Shares of Apogee Therapeutics have gained 34% over the past two days as the small biotech looks to take on Regeneron and Sanofi.

The Guardian - UK

NHS could pay 25% more for medicines under plan to end row with drugmakers and Trump

UK ministers preparing to raise payments to end standoff with pharma industry, cited as reason for firms axing British investments

Kiplinger

Major Insurers Scale Back Medicare Advantage and Part D Plans for 2026

Beneficiaries enrolled in Medicare Advantage and Part D prescription drug plans might be losing their plan as UnitedHealthcare, Humana, and Aetna (CVS Health) scale back offerings for 2026.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

How Arcus Biosciences Aims To Take On Merck In Cancer Treatment

Arcus Biosciences reversed lower Tuesday, though analysts say enthusiasm is growing for the company's cancer drug, a rival to Merck.

The Texas Tribune

$68 million COVID-era federal funding loss and other potential cuts threaten Texas opioid fight

In addition to the cuts, local nonprofits are also having problems accessing federal help for opioid reversal medication, such as Narcan.

The Guardian - US

Anti-abortion groups furious as FDA approves generic abortion pill

Abortion rights supporters hail win for evidence-backed medicine as Evita Solutions’ generic version of mifepristone given approval

Kiplinger

The Best Biotech ETFs to Buy

Biotech ETFs offer investors exposure to the most innovative and growth-oriented industry within the traditionally defensive healthcare sector.

Axios

Inside the TrumpRx website and its unusual launch

Trump has been urging prescription drug manufacturers to lower U.S. prices.

Investors Business Daily

Why Drug Stocks Are Celebrating Trump's 100% Pharmaceutical Tariff

Drug stocks are celebrating in the wake of Trump's threat to levy a 100% tariff on certain pharmaceutical imports.

The Guardian - UK

Big pharma is at war with the UK, and the government can’t back down now

The industry has always wanted the NHS to pay more for its drugs; now it is pulling research and investment out of Britain, says director of Global Justice Now Nick Dearden

1 2 3 4 5

People

Lars Fruergaard Jørgensen

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.